Picture [iito] Made Without Love 650x80px
Collaboration › Details

Iksuda Therapeutics–Univ Göttingen: antibody-drug conjugates, 202010– license excl ww to new class of prodrug payloads for ADCs using PermaLink


Period Period 2020-10-13
Region Region ALL
Organisations Partner, 1st Iksuda Therapeutics Ltd.
  Partner, 2nd MBM ScienceBridge GmbH
  Group University of Göttingen (Georg August University)
Products Product cancer drug
  Product 2 PermaLink™ technology platform

Iksuda Therapeutics Ltd.. (10/13/20). "Press Release: Iksuda Therapeutics Enters License Agreement with University of Goettingen to Develop a New Generation of Antibody Drug Conjugates". Newcastle.

> Iksuda licenses novel protein-alkylating, tumour-activated pro-drug payload series to develop ADCs with enhanced therapeutic index

> Development to focus on targets associated with haematological and solid tumours 

Iksuda Therapeutics (Iksuda), the developer of enhanced, new-generation of Antibody Drug Conjugates (ADCs), today announces it has executed its option to secure exclusive, worldwide rights to develop a novel class of tumour-activated prodrug payloads from the University of Goettingen, following a successful collaboration exemplifying the series in ADC formats. The highly potent and selective payload series represents a powerful new class within ADC development with novel protein alkylating cytotoxicity. Iksuda will drive onward development and commercialisation, incorporating the tuneable payload series in its ADC pipeline and payload armoury, to create best in class ADC therapeutics for nominated targets associated with haematological and solid tumours with high unmet need.

The partnership with the University of Goettingen was founded on Iksuda’s commitment to expand its payload armoury and optimise ADC design according to target antigen. The programme confirmed the value of tumour-selective activation of these powerful cytotoxic agents, conjugated with Iksuda’s stable conjugation technology (PermaLink®), in widening the therapeutic index of ADCs. The novel protein-alkylating mode-of-action of the payload series differs from the field’s primary focus of intra- or DNA inter-strand cross-linking, conferring benefits against drug resistance mechanisms. Through the combination of PermaLink technology and the protein alkylating prodrugs, the Company aims to enable the differentiated development of more powerful ADCs with improved tumour killing, aligned with improved safety index and an ability to overcome potential tumour resistance.

Iksuda has demonstrated the potential value of prodrug approaches for targeted cancer therapeutics through its recent license of a CD19-targeting ADC from LegoChem Biosciences (“LCB”) for hard-to-treat B-cell cancers, including diffuse large B-cell lymphoma and Burkitt lymphoma. The ADC contains LCB’s prodrug DNA-cross-linking payload, with preclinical data confirming an impressive increase in therapeutic index over comparators. Under a broader agreement, the Company has gained access to LCB’s prodrug payload platform for use in nominated Iksuda targets.

Dr Dave Simpson, PhD, Chief Executive Officer, Iksuda Therapeutics, said: “Iksuda’s successful partnership with the University of Goettingen, led by Professor Lutz Tietze, and subsequent licensing agreement demonstrates our continued work in building and refining approaches to ADC development. We are successfully responding to the industry-wide challenge of being able to treat all patients with cancer. Iksuda remains focussed on building a pipeline of next-generation ADCs with improved therapeutic index through our internal and external pipeline, harnessing our deep understanding in the field and accepting the challenge of targeting areas of high unmet clinical need.”

Dr Jens-Peter Horst, PhD, Chief Executive Officer, MBM ScienceBridge, the technology transfer organisation of the University of Goettingen, said: “This agreement is exemplary for the successful transfer of many years of academic research and development work into a very promising and innovative cancer therapy.”


Notes to Editors

Dr Dave Simpson, PhD, CEO, Iksuda Therapeutics
For a high-resolution image please contact Zyme Communications

For further information please contact:

Iksuda Therapeutics

Dave Simpson, Chief Executive Officer
Tel: +44 (0) 191 6031680

Simon Conway / Rob Winder, FTI Consulting (Financial Media and IR)
Tel: +44 (0) 020 3727 1000

Zyme Communications (Trade and Regional Media)
Lorna Cuddon
Tel: +44 (0) 7811 996 942

University of Goettingen/ MBM ScienceBridge  

Tel: +49 (0) 551 30724 151

About Iksuda Therapeutics:

Iksuda Therapeutics is a biotechnology company focussed on the development of enhanced new generation Antibody Drug Conjugates (ADCs) designed to combat difficult-to-treat tumours, including those that are resistant or refractory to current treatment regimens. Iksuda’s pipeline of stable and superior ADCs is centred on its highly stable PermaLink® conjugation platform in combination with a portfolio of highly potent cytotoxic payloads, including prodrugs, designed to enhance antitumor activity and improve the lives of cancer patients.

Record changed: 2021-06-09


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Iksuda Therapeutics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner Network in German Capital Region 650x80px

» top